DNA methylome analyses implicate fallopian tube epithelia as the origin for high-grade serous ovarian cancer

Molecular Cancer Research

Volumn 14, Issue 9, 2016, Pages 787-794

  Klinkebiel, David ^a   Zhang, Wa ^b   Akers, Stacey N ^c   Odunsi, Kunle ^c   Karpf, Adam R ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA METHYLOME; MESOTHELIN; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CPG ISLAND; DIFFERENTIALLY METHYLATED REGION; DNA METHYLATION; DNA STRUCTURE; EPITHELIUM; FALLOPIAN TUBE; FALLOPIAN TUBE EPITHELIUM; FEMALE; GENE CLUSTER; GENETIC ANALYSIS; GENETIC ANALYZER; GENOME; HIGH GRADE SEROUS OVARIAN CANCER; HOMEOBOX; HUMAN; HUMAN TISSUE; OVARIAN SURFACE EPITHELIUM; OVARIAN TISSUE; OVARY; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; STATISTICAL ANALYSIS; CANCER GRADING; CYSTADENOCARCINOMA; GENETICS; NEOPLASM; OVARY TUMOR; PATHOLOGY;

CYSTADENOCARCINOMA, SEROUS; DNA METHYLATION; EPITHELIUM; FALLOPIAN TUBES; FEMALE; HUMANS; NEOPLASM GRADING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84987905139     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-16-0097     Document Type: Article

References (49)

1. Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC Jr., Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 2015;15:668-79.
2. Silva EG.The origin of epithelial neoplasms of the ovary: an alternative view. Adv Anat Pathol 2016;23:50-7.
3. Ng A, Barker N. Ovary and fimbrial stem cells: biology, niche, and cancer origins. Nat Rev Mol Cell Biol 2015;16:625-38.
4. Dubeau L, Drapkin R. Coming into focus: the nonovarian origins of ovarian cancer. Ann Oncol 2013;24 Suppl 8:viii28-viii35.
5. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol 1998;25:281-304.
6. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet 1971;2:163.
7. Connolly DC. Animal models of ovarian cancer. Cancer Treat Res 2009; 149:353-91.
8. Garson K, Shaw TJ, Clark KV, Yao DS, Vanderhyden BC. Models of ovarian cancer-are we there yet? Mol Cell Endocrinol 2005;239:15-26.
9. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34:433-43.
10. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 2007;5:35-44.
11. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010;2010:932371.
12. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195: 451-6.
13. Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 2011; 17:55-67.
14. O'Shannessy DJ, Jackson SM, Twine NC, Hoffman BE, Dezso Z, Agoulnik SI, et al. Gene expression analyses support fallopian tube epithelium as the cell oforigin of epithelial ovarian cancer. Int J Mol Sci 2013;14:13687-703.
15. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, et al. Patterns of gene expressionindifferent histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005;11:6116-26.
16. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 2013;24:751-65.
17. Seisenberger S, Peat JR, Hore TA, Santos F, Dean W, Reik W. Reprogram-ming DNA methylation in the mammalian life cycle: building and breaking epigenetic barriers. Philos Trans R Soc Lond B Biol Sci 2013;368: 20110330.
18. Lokk K, Modhukur V, Rajashekar B, Martens K, Magi R, Kolde R, et al. DNA methylome profiling of human tissues identifies global and tissue-specific methylation patterns. Genome Bio 2014;15:r54.
19. Wan J, Oliver VF, Wang G, Zhu H, Zack DJ, Merbs SL, et al. Characterization of tissue-specific differential DNA methylation suggests distinct modes of positive and negative gene expression regulation. BMC Genomics 2015; 16:49.
20. Oliver VF, Wan J, Agarwal S, Zack DJ, Qian J, Merbs SL. A novel methyl-binding domain protein enrichment method for identifying genome-wide tissue-specific DNA methylation from nanogram DNA samples. Epige-netics Chromatin 2013;6:17.
21. Liang P, Song F, Ghosh S, Morien E, Qin M, Mahmood S, et al. Genome-wide survey reveals dynamic widespread tissue-specific changes in DNA methylation during development. BMC Genomics 2011;12:231.
22. Schultz MD, He Y, Whitaker JW, Hariharan M, Mukamel EA, Leung D, et al. Human body epigenome maps reveal noncanonical DNA methylation variation. Nature 2015;523:212-6.
23. Robertson KD.DNA methylation and human disease. Nat Rev Genet 2005;6:597-610.
24. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92.
25. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypo-and hypermethyla-tion at conserved tissue-specific CpG island shores. Nat Genet 2009;41: 178-86.
26. Sproul D, Kitchen RR, Nestor CE, Dixon JM, Sims AH, Harrison DJ, et al. Tissue of origin determines cancer-associated CpG island promoter hyper-methylation patterns. Genome Biol 2012;13:R84.
27. Ziller MJ, Gu H, Muller F, Donaghey J, Tsai LT, Kohlbacher O, et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 2013;500:477-81.
28. Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, et al. Integrative analysis of 111 reference human epigenomes. Nature 2015;518:317-30.
29. Akers SN, Moysich K, Zhang W, Collamat Lai G, Miller A, Lele S, et al. LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients. Gynecol Oncol 2014;132: 462-7.
30. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. DNA methylation-dependentregulation of BORIS/CTCFL expression inovarian cancer. Cancer Immun 2007;7:21.
31. Woloszynska-Read A, Zhang W, Yu J, Link PA, Mhawech-Fauceglia P, Collamat G, et al. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res 2011; 17:2170-80.
32. Lee EJ, Pei L, Srivastava G, Joshi T, Kushwaha G, Choi JH, et al. Targeted bisulfite sequencing by solution hybrid selection and massively parallel sequencing. Nucleic Acids Res 2011;39:e127.
33. Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 2011;27:1571-2.
34. Patch A-M, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015;521:489-94.
35. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-15.
36. Assenov Y, Muller F, Lutsik P, Walter J, Lengauer T, Bock C. Comprehensive analysis of DNA methylation data with RnBeads. Nat Methods 2014;11:1138-40.
37. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, et al. Differential methylation of tissue-and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibro-blasts. Nat Genet 2009;41:1350-3.
38. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 2010;26:841-2.
39. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, et al. TM4 Microarray Software Suite. Methods Enzymol 2006;411:134-93.
40. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95:14863-8.
41. Wu H, Xu T, Feng H, Chen L, Li B, Yao B, et al. Detection of differentially methylated regions from whole-genome bisulfite sequencing data without replicates. Nucleic Acids Res 2015;43:e141.
42. Holland PW. Evolution of homeobox genes. Wiley Interdisciplinary Rev Devel Biol 2013;2:31-45.
43. Marzese DM, Scolyer RA, Huynh JL, Huang SK, Hirose H, Chong KK, et al. Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeo-box D cluster associated with prognosis. Human Mol Genet 2014; 23:226-38.
44. Oda M, Yamagiwa A, Yamamoto S, Nakayama T, Tsumura A, Sasaki H, et al. DNA methylation regulates long-range gene silencing of an X-linked homeobox gene cluster in a lineage-specific manner. Gen Devel 2006;20: 3382-94.
45. Miller KR, Patel JN, Ganapathi MK, Tait DL, Ganapathi RN. Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer. Gynecol Oncol 2016;141:608-15.
46. Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, et al. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol 2012; 124:582-8.
47. Fang F, Munck J, Tang J, Taverna P, Wang Y, Miller DF, et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin Cancer Res 2014;20:6504-16.
48. Ong CT, Corces VG. Enhancer function: new insights into the regulation of tissue-specific gene expression. Nat Rev Genet 2011;12:283-93.
49. How Kit A, Nielsen HM, Tost J. DNA methylation-based biomarkers: practical considerations and applications. Biochimie 2012;94:2314-37.